Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice

Table 1

Effects of pioglitazone on the expression of fatty acid metabolism related genes in the liver of KKAy mice.

	Nor	Con	Piog
SREBP-1	0.41 ± 0.05**	1.00 ± 0.02	0.81 ± 0.05*
FASN	0.44 ± 0.11**	1.00 ± 0.18	2.50 ± 0.58*
SCD-1	0.98 ± 0.05	1.00 ± 0.16	2.11 ± 0.35**
DGAT-2	1.67 ± 0.09*	1.00 ± 0.27	1.74 ± 0.12**
ACC	0.39 ± 0.06**	1.00 ± 0.07	1.31 ± 0.25
ACOX-1	0.35 ± 0.08**	1.00 ± 0.10	1.80 ± 0.38*
CPT-1a	1.60 ± 0.15**	1.00 ± 0.22	0.56 ± 0.09**
FATP-1	1.90 ± 0.33*	1.00 ± 0.02	0.97 ± 0.10
mCAD	0.38 ± 0.03**	1.00 ± 0.13	1.14 ± 0.07
ApoB	0.35 ± 0.06**	1.00 ± 0.07	0.58 ± 0.06**
ApoC2	0.50 ± 0.04**	1.00 ± 0.07	0.58 ± 0.06**
ApoC3	1.61 ± 0.10**	1.00 ± 0.04	0.49 ± 0.04**
MTTP	1.07 ± 0.23	1.00 ± 0.02	0.60 ± 0.08**
ATGL	2.29 ± 0.19**	1.00 ± 0.04	1.31 ± 0.21
HSL	1.49 ± 0.31	1.00 ± 0.04	0.78 ± 0.03*
PPARα	0.27 ± 0.07**	1.00 ± 0.01	0.81 ± 0.09
PPARβ	0.94 ± 0.11	1.00 ± 0.02	0.70 ± 0.04**

The mRNA expression was examined by using the real-time PCR. Results are expressed as fold change, after correction for β-actin levels, relative to the control mice. Nor: C57BL/6J mice; Con: vehicle-treated KKAy mice; Piog: pioglitazone-treated KKAy mice. Data are presented as mean ± S.E.M. (𝑛 = 6–8 per group). ^∗𝑃<0.05, ^∗∗𝑃<0.01 versus Con.
SREBP-1: sterol regulatory element binding transcription factor 1; FASN: fatty acid synthase; SCD1: stearoyl-coenzyme A desaturase 1; DGAT-2: diacylglycerol O-acyltransferase 2; ACC: acetyl-coenzyme A carboxylase; ACOX-1: acyl-coenzyme A oxidase 1; CPT-1a: carnitine-palmitoyltransferase1a; FATP-1: long-chain fatty acid transport protein 1; mCAD: middle-chain acyl-CoA dehydrogenase; ApoB: apolipoprotein B; ApoC2: apolipoprotein C-II; ApoC3: apolipoprotein C-III; MTTP: microsomal triglyceride transfer protein; ATGL: adipose triglyceride lipase; HSL: hormone sensitive lipase; PPARα: peroxisome proliferator activated receptor alpha; PPARβ/δ: peroxisome proliferator activated receptor delta.